Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bisphosphonates Facing Riskier Committee As FDA Adds Esophageal Cancer To Advisory Panel Agenda

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA revises topics for September committee two weeks after announcing the meeting.

You may also be interested in...



Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee

FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."

Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee

FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."

Safety of Bisphosphonates To Be Reviewed By FDA Advisory Committees

The Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees will meet Sept. 9 to review the safety of long-term use of bisphosphonates in treating osteoporosis.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel